Altogether, these studies suggest that although JAM-A expressed by tumor cells may have a protective role on progression of cancer, JAM-A antagonism could enhance immune response against these abnormal cells by possibly facilitating leukocyte infiltration into tumors and DC egress to LNs (see Figure 2). Here, F11R is linked to neoplasm.